Cargando…

NIR‐II Excitation Phototheranostic Platform for Synergistic Photothermal Therapy/Chemotherapy/Chemodynamic Therapy of Breast Cancer Bone Metastases

To improve bone metastases treatment efficacy, current strategies are focused on the integration of chemotherapy with phototheranostic. However, the success of phototheranostic approaches is hampered by the limited tissue penetration depth of near‐infrared‐I (NIR‐I) light (700–900 nm). In this study...

Descripción completa

Detalles Bibliográficos
Autores principales: Sun, Pengfei, Qu, Fan, Zhang, Chi, Cheng, Pengfei, Li, Xiangyu, Shen, Qingming, Li, Daifeng, Fan, Quli
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9685450/
https://www.ncbi.nlm.nih.gov/pubmed/36216756
http://dx.doi.org/10.1002/advs.202204718
_version_ 1784835508370669568
author Sun, Pengfei
Qu, Fan
Zhang, Chi
Cheng, Pengfei
Li, Xiangyu
Shen, Qingming
Li, Daifeng
Fan, Quli
author_facet Sun, Pengfei
Qu, Fan
Zhang, Chi
Cheng, Pengfei
Li, Xiangyu
Shen, Qingming
Li, Daifeng
Fan, Quli
author_sort Sun, Pengfei
collection PubMed
description To improve bone metastases treatment efficacy, current strategies are focused on the integration of chemotherapy with phototheranostic. However, the success of phototheranostic approaches is hampered by the limited tissue penetration depth of near‐infrared‐I (NIR‐I) light (700–900 nm). In this study, a NIR‐II (1000–1700 nm) excitation phototheranostic (BTZ/Fe(2+)@BTF/ALD) is presented for NIR‐II fluorescence imaging and NIR‐II photoacoustic imaging‐guided NIR‐II photothermal therapy (PTT), chemotherapy, and chemodynamic therapy (CDT) of breast cancer bone metastases. This phototheranostic is developed by integrating a dopamine‐modified NIR‐II absorbing donor–acceptor–donor small molecule (BBT‐FT‐DA), the boronate anticancer drug bortezomib (BTZ), and Fe(2+) ions, as CDT catalysts, into an amphiphilic PEGylated phospholipid modified with the bone‐targeting ligand alendronate. In acidic and hydrogen peroxide (H(2)O(2)) over expression tumor microenvironment, the boronate–catechol linkage is cleaved and BTZ and Fe(2+) ions are released to initiate the Fenton reaction, that is, chemotherapy and CDT, respectively, are initialized. It is confirmed using the murine 4T1 bone metastasis model that BTZ/Fe(2+)@BTF/ALD significantly suppresses the progression of tumor cells in the bone tissue via a synergistic NIR‐II PTT/chemotherapy/CDT effect. Overall, this work provides fresh insights to guide the development of NIR‐II phototheranostics for breast cancer bone metastases.
format Online
Article
Text
id pubmed-9685450
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-96854502022-11-25 NIR‐II Excitation Phototheranostic Platform for Synergistic Photothermal Therapy/Chemotherapy/Chemodynamic Therapy of Breast Cancer Bone Metastases Sun, Pengfei Qu, Fan Zhang, Chi Cheng, Pengfei Li, Xiangyu Shen, Qingming Li, Daifeng Fan, Quli Adv Sci (Weinh) Research Articles To improve bone metastases treatment efficacy, current strategies are focused on the integration of chemotherapy with phototheranostic. However, the success of phototheranostic approaches is hampered by the limited tissue penetration depth of near‐infrared‐I (NIR‐I) light (700–900 nm). In this study, a NIR‐II (1000–1700 nm) excitation phototheranostic (BTZ/Fe(2+)@BTF/ALD) is presented for NIR‐II fluorescence imaging and NIR‐II photoacoustic imaging‐guided NIR‐II photothermal therapy (PTT), chemotherapy, and chemodynamic therapy (CDT) of breast cancer bone metastases. This phototheranostic is developed by integrating a dopamine‐modified NIR‐II absorbing donor–acceptor–donor small molecule (BBT‐FT‐DA), the boronate anticancer drug bortezomib (BTZ), and Fe(2+) ions, as CDT catalysts, into an amphiphilic PEGylated phospholipid modified with the bone‐targeting ligand alendronate. In acidic and hydrogen peroxide (H(2)O(2)) over expression tumor microenvironment, the boronate–catechol linkage is cleaved and BTZ and Fe(2+) ions are released to initiate the Fenton reaction, that is, chemotherapy and CDT, respectively, are initialized. It is confirmed using the murine 4T1 bone metastasis model that BTZ/Fe(2+)@BTF/ALD significantly suppresses the progression of tumor cells in the bone tissue via a synergistic NIR‐II PTT/chemotherapy/CDT effect. Overall, this work provides fresh insights to guide the development of NIR‐II phototheranostics for breast cancer bone metastases. John Wiley and Sons Inc. 2022-10-10 /pmc/articles/PMC9685450/ /pubmed/36216756 http://dx.doi.org/10.1002/advs.202204718 Text en © 2022 The Authors. Advanced Science published by Wiley‐VCH GmbH https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Articles
Sun, Pengfei
Qu, Fan
Zhang, Chi
Cheng, Pengfei
Li, Xiangyu
Shen, Qingming
Li, Daifeng
Fan, Quli
NIR‐II Excitation Phototheranostic Platform for Synergistic Photothermal Therapy/Chemotherapy/Chemodynamic Therapy of Breast Cancer Bone Metastases
title NIR‐II Excitation Phototheranostic Platform for Synergistic Photothermal Therapy/Chemotherapy/Chemodynamic Therapy of Breast Cancer Bone Metastases
title_full NIR‐II Excitation Phototheranostic Platform for Synergistic Photothermal Therapy/Chemotherapy/Chemodynamic Therapy of Breast Cancer Bone Metastases
title_fullStr NIR‐II Excitation Phototheranostic Platform for Synergistic Photothermal Therapy/Chemotherapy/Chemodynamic Therapy of Breast Cancer Bone Metastases
title_full_unstemmed NIR‐II Excitation Phototheranostic Platform for Synergistic Photothermal Therapy/Chemotherapy/Chemodynamic Therapy of Breast Cancer Bone Metastases
title_short NIR‐II Excitation Phototheranostic Platform for Synergistic Photothermal Therapy/Chemotherapy/Chemodynamic Therapy of Breast Cancer Bone Metastases
title_sort nir‐ii excitation phototheranostic platform for synergistic photothermal therapy/chemotherapy/chemodynamic therapy of breast cancer bone metastases
topic Research Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9685450/
https://www.ncbi.nlm.nih.gov/pubmed/36216756
http://dx.doi.org/10.1002/advs.202204718
work_keys_str_mv AT sunpengfei niriiexcitationphototheranosticplatformforsynergisticphotothermaltherapychemotherapychemodynamictherapyofbreastcancerbonemetastases
AT qufan niriiexcitationphototheranosticplatformforsynergisticphotothermaltherapychemotherapychemodynamictherapyofbreastcancerbonemetastases
AT zhangchi niriiexcitationphototheranosticplatformforsynergisticphotothermaltherapychemotherapychemodynamictherapyofbreastcancerbonemetastases
AT chengpengfei niriiexcitationphototheranosticplatformforsynergisticphotothermaltherapychemotherapychemodynamictherapyofbreastcancerbonemetastases
AT lixiangyu niriiexcitationphototheranosticplatformforsynergisticphotothermaltherapychemotherapychemodynamictherapyofbreastcancerbonemetastases
AT shenqingming niriiexcitationphototheranosticplatformforsynergisticphotothermaltherapychemotherapychemodynamictherapyofbreastcancerbonemetastases
AT lidaifeng niriiexcitationphototheranosticplatformforsynergisticphotothermaltherapychemotherapychemodynamictherapyofbreastcancerbonemetastases
AT fanquli niriiexcitationphototheranosticplatformforsynergisticphotothermaltherapychemotherapychemodynamictherapyofbreastcancerbonemetastases